{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:22:32Z","timestamp":1794021752587,"version":"4.8.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02886-9","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:46:59Z","timestamp":1752504419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Pathological mechanisms and treatment progression of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"30","author":[{"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 17(3): 327\u2013406.","DOI":"10.1002\/alz.12328"},{"issue":"24","key":"2886_CR2","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R. Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules. 2020;25(24):5789.","journal-title":"Molecules"},{"issue":"5","key":"2886_CR3","first-page":"S281","volume":"51","author":"BP Leifer","year":"2003","unstructured":"Leifer BP. Early diagnosis of Alzheimer\u2019s disease: clinical and economic benefits. J Am Geriatr Soc. 2003;51(5):S281\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2886_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E. The cellular phase of Alzheimer\u2019s disease. Cell. 2016;164(4):603\u201315.","journal-title":"Cell"},{"issue":"2","key":"2886_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/biom13020313","volume":"13","author":"W Cai","year":"2023","unstructured":"Cai W, Wu T, Chen N. The amyloid-beta clearance: from molecular targets to glial and neural cells. Biomolecules. 2023;13(2):313.","journal-title":"Biomolecules"},{"issue":"5","key":"2886_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12802","volume":"17","author":"X Xia","year":"2018","unstructured":"Xia X, Jiang Q, McDermott J, Han JJ. Aging and Alzheimer\u2019s disease: comparison and associations from molecular to system level. Aging Cell. 2018;17(5): e12802.","journal-title":"Aging Cell"},{"issue":"8006","key":"2886_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","volume":"628","author":"MS Haney","year":"2024","unstructured":"Haney MS, P\u00e1lovics R, Munson CN, Long C, Johansson PK, Yip O, Dong W, Rawat E, West E, Schlachetzki JCM, Tsai A, Guldner IH, Lamichhane BS, Smith A, Schaum N, Calcuttawala K, Shin A, Wang YH, Wang C, Koutsodendris N, Serrano GE, Beach TG, Reiman EM, Glass CK, Abu-Remaileh M, Enejder A, Huang Y, Wyss-Coray T. APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia. Nature. 2024;628(8006):154\u201361.","journal-title":"Nature"},{"issue":"1","key":"2886_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/ijms20010081","volume":"20","author":"CM Wolfe","year":"2018","unstructured":"Wolfe CM, Fitz NF, Nam KN, Lefterov I, Koldamova R. The role of APOE and TREM2 in Alzheimer\u2019s disease-current understanding and perspectives. Int J Mol Sci. 2018;20(1):81.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2886_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023;19(12):715\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"2886_CR10","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1002\/alz.13875","volume":"20","author":"Y Yao","year":"2024","unstructured":"Yao Y, Muench M, Alle T, Zhang B, Lucero B, Perez-Tremble R, McGrosso D, Newman M, Gonzalez DJ, Lee VM, Ballatore C, Brunden KR. A small-molecule microtubule-stabilizing agent safely reduces A\u03b2 plaque and tau pathology in transgenic mouse models of Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(7):4540\u201358.","journal-title":"Alzheimers Dement"},{"key":"2886_CR11","doi-asserted-by":"publisher","first-page":"1042986","DOI":"10.3389\/fbioe.2022.1042986","volume":"10","author":"Y Cao","year":"2022","unstructured":"Cao Y, Zhang R. The application of nanotechnology in treatment of Alzheimer\u2019s disease. Front Bioeng Biotechnol. 2022;10:1042986.","journal-title":"Front Bioeng Biotechnol"},{"key":"2886_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100789","volume":"22","author":"T Yin","year":"2023","unstructured":"Yin T, Liu Y, He B, Gong B, Chu J, Gao C, Liang W, Hao M, Sun W, Zhuang J, Gao J, Yin Y. Cell primitive-based biomimetic nanomaterials for Alzheimer\u2019s disease targeting and therapy. Mater Today Bio. 2023;22: 100789.","journal-title":"Mater Today Bio"},{"key":"2886_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/23279095.2025.2469236","author":"E Soncu B\u00fcy\u00fcki\u015fcan","year":"2025","unstructured":"Soncu B\u00fcy\u00fcki\u015fcan E. Neuropsychology of Alzheimer\u2019s disease: from preclinical phase to dementia. Appl Neuropsychol Adult. 2025. https:\/\/doi.org\/10.1080\/23279095.2025.2469236.","journal-title":"Appl Neuropsychol Adult"},{"issue":"9","key":"2886_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.molmed.2022.05.008","volume":"28","author":"J Therriault","year":"2022","unstructured":"Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-Neto P. Staging of Alzheimer\u2019s disease: past, present, and future perspectives. Trends Mol Med. 2022;28(9):726\u201341.","journal-title":"Trends Mol Med"},{"issue":"4","key":"2886_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/pin.12520","volume":"67","author":"RH Takahashi","year":"2017","unstructured":"Takahashi RH, Nagao T, Gouras GK. Plaque formation and the intraneuronal accumulation of \u03b2-amyloid in Alzheimer\u2019s disease. Pathol Int. 2017;67(4):185\u201393.","journal-title":"Pathol Int"},{"issue":"2","key":"2886_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.14336\/AD.2024.0286","volume":"16","author":"JA Pradeepkiran","year":"2024","unstructured":"Pradeepkiran JA, Baig J, Islam MA, Kshirsagar S, Reddy PH. Amyloid-\u03b2 and phosphorylated tau are the key biomarkers and predictors of Alzheimer\u2019s disease. Aging Dis. 2024;16(2):658\u201382.","journal-title":"Aging Dis"},{"issue":"1","key":"2886_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2886_CR18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.neurobiolaging.2005.05.022","volume":"26","author":"GK Gouras","year":"2005","unstructured":"Gouras GK, Almeida CG, Takahashi RH. Intraneuronal A\u03b2 accumulation and origin of plaques in Alzheimer\u2019s disease. Neurobiol Aging. 2005;26(9):1235\u201344.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2886_CR19","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts. Nat Commun. 2023;14(1):6747.","journal-title":"Nat Commun"},{"issue":"1","key":"2886_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-020-00195-1","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Tian DY, Wang YJ. Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives. Transl Neurodegener. 2020;9(1):16.","journal-title":"Transl Neurodegener"},{"issue":"9","key":"2886_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"G-F Chen","year":"2017","unstructured":"Chen G-F, Xu T-H, Yan Y, Zhou Y-R, Jiang Y, Melcher K, Xu HE. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"2886_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nn.4188","volume":"19","author":"U Das","year":"2016","unstructured":"Das U, Wang L, Ganguly A, Saikia JM, Wagner SL, Koo EH, Roy S. Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat Neurosci. 2016;19(1):55\u201364.","journal-title":"Nat Neurosci"},{"issue":"3","key":"2886_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002270","volume":"14","author":"HM Lanoisel\u00e9e","year":"2017","unstructured":"Lanoisel\u00e9e HM, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, Richard AC, Pasquier F, Rollin-Sillaire A, Martinaud O, Quillard-Muraine M, de la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx F, Chauvir\u00e9 V, Sarazin M, le Ber I, Epelbaum S, Jonveaux T, Rouaud O, Ceccaldi M, F\u00e9lician O, Godefroy O, Formaglio M, Croisile B, Auriacombe S, Chamard L, Vincent JL, Sauv\u00e9e M, Marelli-Tosi C, Gabelle A, Ozsancak C, Pariente J, Paquet C, Hannequin D, Campion D. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLoS Med. 2017;14(3): e1002270.","journal-title":"PLoS Med"},{"key":"2886_CR24","first-page":"1163","volume":"10","author":"Y Cai","year":"2015","unstructured":"Cai Y, An SS, Kim S. Mutations in presenilin 2 and its implications in Alzheimer\u2019s disease and other dementia-associated disorders. Clin Interv Aging. 2015;10:1163\u201372.","journal-title":"Clin Interv Aging"},{"issue":"7","key":"2886_CR25","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1007\/s12035-023-03847-1","volume":"61","author":"P W\u00f3jcik","year":"2024","unstructured":"W\u00f3jcik P, Jastrz\u0119bski MK, Zi\u0119ba A, Matosiuk D, Kaczor AA. Caspases in Alzheimer\u2019s disease: mechanism of activation role, and potential treatment. Mol Neurobiol. 2024;61(7):4834\u201353.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"2886_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jnc.12202","volume":"126","author":"L Gu","year":"2013","unstructured":"Gu L, Guo Z. Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126(3):305\u201311.","journal-title":"J Neurochem"},{"issue":"4","key":"2886_CR27","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.3892\/mmr.2017.7203","volume":"16","author":"XJ Han","year":"2017","unstructured":"Han XJ, Hu YY, Yang ZJ, Jiang LP, Shi SL, Li YR, Guo MY, Wu HL, Wan YY. Amyloid \u03b2-42 induces neuronal apoptosis by targeting mitochondria. Mol Med Rep. 2017;16(4):4521\u20138.","journal-title":"Mol Med Rep"},{"issue":"1","key":"2886_CR28","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1038\/s41467-025-60328-w","volume":"16","author":"A Caramello","year":"2025","unstructured":"Caramello A, Fancy N, Tournerie C, Eklund M, Chau V, Adair E, Papageorgopoulou M, Willumsen N, Jackson JS, Hardy J, Matthews PM. Intracellular accumulation of amyloid-\u00df is a marker of selective neuronal vulnerability in Alzheimer\u2019s disease. Nat Commun. 2025;16(1):5189.","journal-title":"Nat Commun"},{"issue":"3","key":"2886_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"2886_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","volume":"11","author":"P Barbier","year":"2019","unstructured":"Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C, Tsvetkov PO, Devred F, Landrieu I. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci. 2019;11:204.","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"2886_CR31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2174\/1568026620666200106125910","volume":"20","author":"AA Turab Naqvi","year":"2020","unstructured":"Turab Naqvi AA, Hasan GM, Hassan MI. Targeting tau hyperphosphorylation via kinase inhibition: strategy to address Alzheimer\u2019s disease. Curr Top Med Chem. 2020;20(12):1059\u201373.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"2886_CR32","first-page":"24","volume":"13","author":"H Dixit","year":"2021","unstructured":"Dixit H, Kumar CS, Chaudhary R, Thaker D, Gadewal N, Dasgupta D. Role of phosphorylation and hyperphosphorylation of tau in its interaction with \u03b2\u03b1 dimeric tubulin studied from a bioinformatics perspective. Avicenna J Med Biotechnol. 2021;13(1):24\u201334.","journal-title":"Avicenna J Med Biotechnol"},{"key":"2886_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.707268","volume":"9","author":"H Zhang","year":"2021","unstructured":"Zhang H, Cao Y, Ma L, Wei Y, Li H. Possible mechanisms of tau spread and toxicity in Alzheimer\u2019s disease. Front Cell Dev Biol. 2021;9: 707268.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2886_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neuint.2012.04.019","volume":"61","author":"LL Shi","year":"2012","unstructured":"Shi LL, Yang WN, Chen XL, Zhang JS, Yang PB, Hu XD, Han H, Qian YH, Liu Y. The protective effects of tanshinone IIA on neurotoxicity induced by \u03b2-amyloid protein through calpain and the p35\/Cdk5 pathway in primary cortical neurons. Neurochem Int. 2012;61(2):227\u201335.","journal-title":"Neurochem Int"},{"issue":"9","key":"2886_CR35","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, Cao Y, Li H. Interaction between A\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease. Int J Biol Sci. 2021;17(9):2181\u201392.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2886_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00441-011-1230-6","volume":"347","author":"F Caraci","year":"2012","unstructured":"Caraci F, Spampinato S, Sortino MA, Bosco P, Battaglia G, Bruno V, Drago F, Nicoletti F, Copani A. Dysfunction of TGF-\u03b21 signaling in Alzheimer\u2019s disease: perspectives for neuroprotection. Cell Tissue Res. 2012;347(1):291\u2013301.","journal-title":"Cell Tissue Res"},{"issue":"1","key":"2886_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12974-023-02751-8","volume":"20","author":"M Kapoor","year":"2023","unstructured":"Kapoor M, Chinnathambi S. TGF-\u03b21 signalling in Alzheimer\u2019s pathology and cytoskeletal reorganization: a specialized Tau perspective. J Neuroinflammation. 2023;20(1):72.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"2886_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40035-024-00429-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang J, Zhang Z, Ye K. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener. 2024;13(1):40.","journal-title":"Transl Neurodegener"},{"issue":"4","key":"2886_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.medp.2024.100060","volume":"1","author":"J Su","year":"2024","unstructured":"Su J, Xiao Y, Wang X, Zheng J, Wang J-Z. Development of tau phosphorylation-targeting therapies for the treatment of neurodegenerative diseases. Med Plus. 2024;1(4): 100060.","journal-title":"Med Plus"},{"issue":"1","key":"2886_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbamem.2003.10.023","volume":"1662","author":"SG Hormuzdi","year":"2004","unstructured":"Hormuzdi SG, Filippov MA, Mitropoulou G, Monyer H, Bruzzone R. Electrical synapses: a dynamic signaling system that shapes the activity of neuronal networks. Biochim Biophys Acta Biomembr. 2004;1662(1):113\u201337.","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"1","key":"2886_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","volume":"19","author":"M Tzioras","year":"2023","unstructured":"Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19(1):19\u201338.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2886_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1021\/acschemneuro.0c00811","volume":"12","author":"G Fani","year":"2021","unstructured":"Fani G, Mannini B, Vecchi G, Cascella R, Cecchi C, Dobson CM, Vendruscolo M, Chiti F. A\u03b2 oligomers dysregulate calcium homeostasis by mechanosensitive activation of AMPA and NMDA receptors. ACS Chem Neurosci. 2021;12(4):766\u201381.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"2886_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-021-00270-1","volume":"10","author":"M Wu","year":"2021","unstructured":"Wu M, Zhang M, Yin X, Chen K, Hu Z, Zhou Q, Cao X, Chen Z, Liu D. The role of pathological tau in synaptic dysfunction in Alzheimer\u2019s diseases. Transl Neurodegener. 2021;10(1):45.","journal-title":"Transl Neurodegener"},{"key":"2886_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-981-32-9358-8_7","volume":"1184","author":"B Combs","year":"2019","unstructured":"Combs B, Mueller RL, Morfini G, Brady ST, Kanaan NM. Tau and axonal transport misregulation in tauopathies. Adv Exp Med Biol. 2019;1184:81\u201395.","journal-title":"Adv Exp Med Biol"},{"issue":"6463","key":"2886_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/367557a0","volume":"367","author":"JJ O'Connor","year":"1994","unstructured":"O\u2019Connor JJ, Rowan MJ, Anwyl R. Long-lasting enhancement of NMDA receptor-mediated synaptic transmission by metabotropic glutamate receptor activation. Nature. 1994;367(6463):557\u20139.","journal-title":"Nature"},{"issue":"23","key":"2886_CR46","doi-asserted-by":"publisher","first-page":"19377","DOI":"10.1074\/jbc.M111.321448","volume":"287","author":"N Nunes-Tavares","year":"2012","unstructured":"Nunes-Tavares N, Santos LE, Stutz B, Brito-Moreira J, Klein WL, Ferreira ST, de Mello FG. Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-\u03b2 peptide oligomers. J Biol Chem. 2012;287(23):19377\u201385.","journal-title":"J Biol Chem"},{"key":"2886_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fnmol.2011.00019","volume":"4","author":"FJ Carvajal","year":"2011","unstructured":"Carvajal FJ, Inestrosa NC. Interactions of AChE with A\u03b2 aggregates in Alzheimer\u2019s brain: therapeutic relevance of IDN 5706. Front Mol Neurosci. 2011;4:19.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"2886_CR48","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1007\/s12035-017-0533-3","volume":"55","author":"K Li","year":"2018","unstructured":"Li K, Wei Q, Liu FF, Hu F, Xie AJ, Zhu LQ, Liu D. Synaptic dysfunction in Alzheimer\u2019s disease: A\u03b2, Tau, and epigenetic alterations. Mol Neurobiol. 2018;55(4):3021\u201332.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"2886_CR49","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/ijms22052283","volume":"22","author":"YJ Cheng","year":"2021","unstructured":"Cheng YJ, Lin CH, Lane HY. Involvement of cholinergic, adrenergic, and glutamatergic network modulation with cognitive dysfunction in Alzheimer\u2019s disease. Int J Mol Sci. 2021;22(5):2283.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2886_CR50","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.immuni.2021.09.014","volume":"54","author":"K Borst","year":"2021","unstructured":"Borst K, Dumas AA, Prinz M. Microglia: immune and non-immune functions. Immunity. 2021;54(10):2194\u2013208.","journal-title":"Immunity"},{"issue":"1","key":"2886_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10571-014-0101-6","volume":"35","author":"Y Yu","year":"2015","unstructured":"Yu Y, Ye RD. Microglial A\u03b2 receptors in Alzheimer\u2019s disease. Cell Mol Neurobiol. 2015;35(1):71\u201383.","journal-title":"Cell Mol Neurobiol"},{"issue":"3","key":"2886_CR52","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.4049\/jimmunol.1101121","volume":"188","author":"S Liu","year":"2012","unstructured":"Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, R\u00fcbe CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K. TLR2 is a primary receptor for Alzheimer\u2019s amyloid \u03b2 peptide to trigger neuroinflammatory activation. J Immunol. 2012;188(3):1098\u2013107.","journal-title":"J Immunol"},{"issue":"10","key":"2886_CR53","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1007\/s00018-021-03810-0","volume":"78","author":"SF Lau","year":"2021","unstructured":"Lau SF, Fu AKY, Ip NY. Cytokine signaling convergence regulates the microglial state transition in Alzheimer\u2019s disease. Cell Mol Life Sci. 2021;78(10):4703\u201312.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"2886_CR54","first-page":"136","volume":"3","author":"WY Wang","year":"2015","unstructured":"Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease. Ann Transl Med. 2015;3(10):136.","journal-title":"Ann Transl Med"},{"issue":"8","key":"2886_CR55","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.18632\/aging.101518","volume":"10","author":"ML Giuffrida","year":"2018","unstructured":"Giuffrida ML, Copani A, Rizzarelli E. A promising connection between BDNF and Alzheimer\u2019s disease. Aging (Albany NY). 2018;10(8):1791\u20132.","journal-title":"Aging (Albany NY)"},{"key":"2886_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102465","volume":"100","author":"S Kardam","year":"2024","unstructured":"Kardam S, Ambasta RK, Kumar P. Overview of pro-inflammatory and pro-survival components in neuroinflammatory signalling and neurodegeneration. Ageing Res Rev. 2024;100: 102465.","journal-title":"Ageing Res Rev"},{"key":"2886_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.749587","volume":"15","author":"G Zhang","year":"2021","unstructured":"Zhang G, Wang Z, Hu H, Zhao M, Sun L. Microglia in Alzheimer\u2019s disease: a target for therapeutic intervention. Front Cell Neurosci. 2021;15: 749587.","journal-title":"Front Cell Neurosci"},{"key":"2886_CR58","doi-asserted-by":"publisher","first-page":"254248232513418","DOI":"10.1177\/25424823251341870","volume":"9","author":"S Fakorede","year":"2025","unstructured":"Fakorede S, Lateef OM, Garuba WA, Akosile PO, Okon DA, Aborode AT. Dual impact of neuroinflammation on cognitive and motor impairments in Alzheimer\u2019s disease. J Alzheimers Dis Rep. 2025;9:25424823251341870.","journal-title":"J Alzheimers Dis Rep"},{"issue":"3","key":"2886_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"2886_CR60","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/jcm10061299","volume":"10","author":"J Ojeda","year":"2021","unstructured":"Ojeda J, \u00c1vila A, Vidal PM. Gut microbiota interaction with the central nervous system throughout life. J Clin Med. 2021;10(6):1299.","journal-title":"J Clin Med"},{"issue":"6","key":"2886_CR61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41579-024-01136-9","volume":"23","author":"TE Ohara","year":"2025","unstructured":"Ohara TE, Hsiao EY. Microbiota\u2013neuroepithelial signalling across the gut\u2013brain axis. Nat Rev Microbiol. 2025;23(6):371\u201384.","journal-title":"Nat Rev Microbiol"},{"key":"2886_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2024.127858","volume":"287","author":"S Qu","year":"2024","unstructured":"Qu S, Yu Z, Zhou Y, Wang S, Jia M, Chen T, Zhang X. Gut microbiota modulates neurotransmitter and gut-brain signaling. Microbiol Res. 2024;287: 127858.","journal-title":"Microbiol Res"},{"issue":"6","key":"2886_CR63","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/nu13062099","volume":"13","author":"Y Chen","year":"2021","unstructured":"Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients. 2021;13(6):2099.","journal-title":"Nutrients"},{"issue":"1","key":"2886_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41467-017-00040-6","volume":"8","author":"S-C Wu","year":"2017","unstructured":"Wu S-C, Cao Z-S, Chang K-M, Juang J-L. Intestinal microbial dysbiosis aggravates the progression of Alzheimer\u2019s disease in Drosophila. Nat Commun. 2017;8(1):24.","journal-title":"Nat Commun"},{"issue":"5","key":"2886_CR65","volume":"6","author":"Y Shen","year":"2025","unstructured":"Shen Y, Fan N, Ma SX, Cheng X, Yang X, Wang G. Gut microbiota dysbiosis: pathogenesis, diseases, prevention, and therapy. Med Comm. 2025;6(5): e70168.","journal-title":"Med Comm"},{"issue":"2","key":"2886_CR66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/152308601300185223","volume":"3","author":"VE Thiel","year":"2001","unstructured":"Thiel VE, Audus KL. Nitric oxide and blood-brain barrier integrity. Antioxid Redox Signal. 2001;3(2):273\u20138.","journal-title":"Antioxid Redox Signal"},{"key":"2886_CR67","doi-asserted-by":"publisher","first-page":"104714","DOI":"10.1016\/j.neuint.2020.104714","volume":"136","author":"AP de Ara\u00fajo Boleti","year":"2020","unstructured":"de Ara\u00fajo Boleti AP, de Oliveira Flores TM, Moreno SE, Anjos LD, Mortari MR, Migliolo L. Neuroinflammation: an overview of neurodegenerative and metabolic diseases and of biotechnological studies. Neurochem Int. 2020;136:104714.","journal-title":"Neurochem Int"},{"key":"2886_CR68","doi-asserted-by":"publisher","first-page":"1582119","DOI":"10.3389\/fimmu.2025.1582119","volume":"16","author":"W Lei","year":"2025","unstructured":"Lei W, Cheng Y, Liu X, Gao J, Zhu Z, Ding W, Xu X, Li Y, Ling Z, Jiang R, Chen X. Gut microbiota-driven neuroinflammation in Alzheimer\u2019s disease: from mechanisms to therapeutic opportunities. Front Immunol. 2025;16:1582119.","journal-title":"Front Immunol"},{"key":"2886_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2025.113122","author":"OP Vallejos","year":"2025","unstructured":"Vallejos OP, Bueno SM, Kalergis AM. Probiotics in inflammatory bowel disease: microbial modulation and therapeutic prospects. Trends Mol Med. 2025. https:\/\/doi.org\/10.1016\/j.jphotobiol.2025.113122.","journal-title":"Trends Mol Med"},{"issue":"15","key":"2886_CR70","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3390\/cells11152262","volume":"11","author":"L G\u00f3mez-Virgilio","year":"2022","unstructured":"G\u00f3mez-Virgilio L, Silva-Lucero MD, Flores-Morelos DS, Gallardo-Nieto J, Lopez-Toledo G, Abarca-Fernandez AM, Zacapala-G\u00f3mez AE, Luna-Mu\u00f1oz J, Montiel-Sosa F, Soto-Rojas LO, Pacheco-Herrero M. Autophagy: a key regulator of homeostasis and disease: an overview of molecular mechanisms and modulators. Cells. 2022;11(15):2262.","journal-title":"Cells"},{"key":"2886_CR71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.conb.2019.09.010","volume":"59","author":"JY Hwang","year":"2019","unstructured":"Hwang JY, Yan J, Zukin RS. Autophagy and synaptic plasticity: epigenetic regulation. Curr Opin Neurobiol. 2019;59:207\u201312.","journal-title":"Curr Opin Neurobiol"},{"issue":"1","key":"2886_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7555\/JBR.36.20220145","volume":"37","author":"M Yuan","year":"2022","unstructured":"Yuan M, Wang Y, Huang Z, Jing F, Qiao P, Zou Q, Li J, Cai Z. Impaired autophagy in amyloid-beta pathology: a traditional review of recent Alzheimer\u2019s research. J Biomed Res. 2022;37(1):30\u201346.","journal-title":"J Biomed Res"},{"issue":"4","key":"2886_CR73","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.apsb.2021.12.009","volume":"12","author":"Z Deng","year":"2022","unstructured":"Deng Z, Dong Y, Zhou X, Lu J-H, Yue Z. Pharmacological modulation of autophagy for Alzheimer\u2019s disease therapy: Opportunities and obstacles. Acta Pharm Sin B. 2022;12(4):1688\u2013706.","journal-title":"Acta Pharm Sin B"},{"key":"2886_CR74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coph.2021.07.011","volume":"60","author":"BP Festa","year":"2021","unstructured":"Festa BP, Barbosa AD, Rob M, Rubinsztein DC. The pleiotropic roles of autophagy in Alzheimer\u2019s disease: from pathophysiology to therapy. Curr Opin Pharmacol. 2021;60:149\u201357.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"2886_CR75","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11011-021-00737-0","volume":"36","author":"SSM Lai","year":"2021","unstructured":"Lai SSM, Ng KY, Koh RY, Chok KC, Chye SM. Endosomal-lysosomal dysfunctions in Alzheimer\u2019s disease: pathogenesis and therapeutic interventions. Metab Brain Dis. 2021;36(6):1087\u2013100.","journal-title":"Metab Brain Dis"},{"issue":"6","key":"2886_CR76","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jnc.14945","volume":"155","author":"A Lu\u010di\u016bnait\u0117","year":"2020","unstructured":"Lu\u010di\u016bnait\u0117 A, McManus RM, Jankunec M, R\u00e1cz I, Dansokho C, Dalg\u0117dien\u0117 I, Schwartz S, Brosseron F, Heneka MT. Soluble A\u03b2 oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem. 2020;155(6):650\u201361.","journal-title":"J Neurochem"},{"key":"2886_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101202","volume":"65","author":"A-G Wu","year":"2021","unstructured":"Wu A-G, Zhou X-G, Qiao G, Yu L, Tang Y, Yan L, Qiu W-Q, Pan R, Yu C-L, Law BY-K, Qin D-L, Wu J-M. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. Ageing Res Rev. 2021;65: 101202.","journal-title":"Ageing Res Rev"},{"issue":"8","key":"2886_CR78","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jmb.2019.12.035","volume":"432","author":"A Djajadikerta","year":"2020","unstructured":"Djajadikerta A, Keshri S, Pavel M, Prestil R, Ryan L, Rubinsztein DC. Autophagy induction as a therapeutic strategy for neurodegenerative diseases. J Mol Biol. 2020;432(8):2799\u2013821.","journal-title":"J Mol Biol"},{"issue":"8","key":"2886_CR79","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/antiox9080647","volume":"9","author":"A Picca","year":"2020","unstructured":"Picca A, Calvani R, Coelho-Junior HJ, Landi F, Bernabei R, Marzetti E. Mitochondrial dysfunction, oxidative stress, and neuroinflammation: intertwined roads to neurodegeneration. Antioxidants (Basel). 2020;9(8):647.","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"2886_CR80","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jagp.2022.01.009","volume":"30","author":"CJ Rebello","year":"2022","unstructured":"Rebello CJ. Polyunsaturated fatty acid intake and brain health: balance is the key. Am J Geriatr Psychiatry. 2022;30(7):774\u20136.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"2886_CR81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/jpet.116.237503","volume":"360","author":"S Salim","year":"2017","unstructured":"Salim S. Oxidative stress and the central nervous system. J Pharmacol Exp Ther. 2017;360(1):201\u20135.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2886_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00525","volume":"22","author":"KC McGill Percy","year":"2025","unstructured":"McGill Percy KC, Liu Z, Qi X. Mitochondrial dysfunction in Alzheimer\u2019s disease: Guiding the path to targeted therapies. Neurotherapeutics. 2025;22(3): e00525.","journal-title":"Neurotherapeutics"},{"key":"2886_CR83","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","volume":"14","author":"C Cheignon","year":"2018","unstructured":"Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox Biol. 2018;14:450\u201364.","journal-title":"Redox Biol"},{"issue":"6","key":"2886_CR84","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1152\/jn.00287.2010","volume":"105","author":"JG Xue","year":"2011","unstructured":"Xue JG, Masuoka T, Gong XD, Chen KS, Yanagawa Y, Law SK, Konishi S. NMDA receptor activation enhances inhibitory GABAergic transmission onto hippocampal pyramidal neurons via presynaptic and postsynaptic mechanisms. J Neurophysiol. 2011;105(6):2897\u2013906.","journal-title":"J Neurophysiol"},{"issue":"7","key":"2886_CR85","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.3390\/ijms23073785","volume":"23","author":"CG Ardanaz","year":"2022","unstructured":"Ardanaz CG, Ram\u00edrez MJ, Solas M. Brain metabolic alterations in Alzheimer\u2019s disease. Int J Mol Sci. 2022;23(7):3785.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2886_CR86","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s00259-020-05141-x","volume":"48","author":"G Zerbini","year":"2021","unstructured":"Zerbini G, Caminiti SP, Perani D. Hypoglycemia-induced brain hypometabolism captured in real time by FDG-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1686\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2886_CR87","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau VV. Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci. 2020;21(9):3165.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2886_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41392-024-01894-1","volume":"9","author":"JK Sonner","year":"2024","unstructured":"Sonner JK, Mayer C, Friese MA. Microglial complex I activity: a crucial factor for smoldering inflammation in the central nervous system. Signal Transduct Target Ther. 2024;9(1):185.","journal-title":"Signal Transduct Target Ther"},{"key":"2886_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102667","volume":"104","author":"P Wen","year":"2025","unstructured":"Wen P, Sun Z, Gou F, Wang J, Fan Q, Zhao D, Yang L. Oxidative stress and mitochondrial impairment: key drivers in neurodegenerative disorders. Ageing Res Rev. 2025;104: 102667.","journal-title":"Ageing Res Rev"},{"key":"2886_CR90","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3389\/fphar.2019.00902","volume":"10","author":"G Cenini","year":"2019","unstructured":"Cenini G, Voos W. Mitochondria as potential targets in alzheimer disease therapy: an update. Front Pharmacol. 2019;10:902.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2886_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41583-023-00776-9","volume":"25","author":"J Blumenfeld","year":"2024","unstructured":"Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type-specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024;25(2):91\u2013110.","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"2886_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110435","volume":"38","author":"K Lindner","year":"2022","unstructured":"Lindner K, Beckenbauer K, van Ek LC, Titeca K, de Leeuw SM, Awwad K, Hanke F, Korepanova AV, Rybin V, van der Kam EL, Mohler EG, Tackenberg C, Lakics V, Gavin A-C. Isoform- and cell-state-specific lipidation of ApoE in astrocytes. Cell Rep. 2022;38(9): 110435.","journal-title":"Cell Rep"},{"issue":"1","key":"2886_CR93","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/ijms24010778","volume":"24","author":"M Pires","year":"2023","unstructured":"Pires M, Rego AC. Apoe4 and Alzheimer\u2019s disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies. Int J Mol Sci. 2023;24(1):778.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2886_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169131","volume":"133","author":"C Wang","year":"2023","unstructured":"Wang C, Nambiar A, Strickland MR, Lee C, Parhizkar S, Moore AC, Musiek ES, Ulrich JD, Holtzman DM. APOE-\u03b54 synergizes with sleep disruption to accelerate A\u03b2 deposition and A\u03b2-associated tau seeding and spreading. J Clin Invest. 2023;133(14): e169131.","journal-title":"J Clin Invest"},{"issue":"1","key":"2886_CR95","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13024-025-00857-6","volume":"20","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang L, Qin C. Alzheimer\u2019s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response. Mol Neurodegener. 2025;20(1):67.","journal-title":"Mol Neurodegener"},{"issue":"7","key":"2886_CR96","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Aizenstein HJ, Klunk WE, Snitz BE, Maki P, Thurston RC, Cohen AD, Ganguli M, Karikari TK, Rosa-Neto P, Pascoal TA. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2023;29(7):1775\u201381.","journal-title":"Nat Med"},{"issue":"10","key":"2886_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113183","volume":"42","author":"H Lee","year":"2023","unstructured":"Lee H, Cho S, Kim MJ, Park YJ, Cho E, Jo YS, Kim YS, Lee JY, Thoudam T, Woo SH, Lee SI, Jeon J, Lee YS, Suh BC, Yoon JH, Go Y, Lee IK, Seo J. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell Rep. 2023;42(10): 113183.","journal-title":"Cell Rep"},{"issue":"1","key":"2886_CR98","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12944-025-02633-3","volume":"24","author":"Y Li","year":"2025","unstructured":"Li Y, Zhao Q, Wang Y, Du W, Yang R, Wu J, Li Y. Lipid droplet accumulation in microglia and their potential roles. Lipids Health Dis. 2025;24(1):215.","journal-title":"Lipids Health Dis"},{"issue":"11","key":"2886_CR99","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1002\/alz.14317","volume":"20","author":"VJ Lowe","year":"2024","unstructured":"Lowe VJ, Mester CT, Lundt ES, Lee J, Ghatamaneni S, Algeciras-Schimnich A, Campbell MR, Graff-Radford J, Nguyen A, Min HK, Senjem ML, Machulda MM, Schwarz CG, Dickson DW, Murray ME, Kandimalla KK, Kantarci K, Boeve B, Vemuri P, Jones DT, Knopman D, Jack CR Jr, Petersen RC, Mielke MM. Amyloid PET detects the deposition of brain A\u03b2 earlier than CSF fluid biomarkers. Alzheimers Dement. 2024;20(11):8097\u2013112.","journal-title":"Alzheimers Dement"},{"key":"2886_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101594","volume":"59","author":"S Parhizkar","year":"2022","unstructured":"Parhizkar S, Holtzman DM. APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease. Semin Immunol. 2022;59: 101594.","journal-title":"Semin Immunol"},{"key":"2886_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2024.103917","volume":"128","author":"E Zgorzynska","year":"2024","unstructured":"Zgorzynska E. TREM2 in Alzheimer\u2019s disease: structure, function, therapeutic prospects, and activation challenges. Mol Cell Neurosci. 2024;128: 103917.","journal-title":"Mol Cell Neurosci"},{"issue":"11","key":"2886_CR102","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M. TREM2\u2014a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14(11):667\u201375.","journal-title":"Nat Rev Neurol"},{"issue":"19","key":"2886_CR103","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1093\/hmg\/ddaa209","volume":"29","author":"W Liu","year":"2020","unstructured":"Liu W, Taso O, Wang R, Bayram S, Graham AC, Garcia-Reitboeck P, Mallach A, Andrews WD, Piers TM, Botia JA, Pocock JM, Cummings DM, Hardy J, Edwards FA, Salih DA. Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. Hum Mol Genet. 2020;29(19):3224\u201348.","journal-title":"Hum Mol Genet"},{"key":"2886_CR104","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.20391","volume":"5","author":"DL Kober","year":"2016","unstructured":"Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, Brett TJ. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5: e20391.","journal-title":"Elife"},{"issue":"1","key":"2886_CR105","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-018-0262-8","volume":"13","author":"PJ Cheng-Hathaway","year":"2018","unstructured":"Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, von Saucken VE, Williams RY, Karlo JC, Moutinho M, Xu G, Ransohoff RM, Lamb BT, Landreth GE. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13(1):29.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"2886_CR106","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrn.2016.7","volume":"17","author":"M Colonna","year":"2016","unstructured":"Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17(4):201\u20137.","journal-title":"Nat Rev Neurosci"},{"issue":"27","key":"2886_CR107","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1523\/JNEUROSCI.2427-21.2022","volume":"42","author":"Q Shi","year":"2022","unstructured":"Shi Q, Chang C, Saliba A, Bhat MA. Microglial mTOR activation upregulates Trem2 and enhances \u03b2-amyloid plaque clearance in the 5XFAD Alzheimer\u2019s disease model. J Neurosci. 2022;42(27):5294\u2013313.","journal-title":"J Neurosci"},{"issue":"49","key":"2886_CR108","doi-asserted-by":"publisher","first-page":"33927","DOI":"10.1074\/jbc.M114.608091","volume":"289","author":"D Paris","year":"2014","unstructured":"Paris D, Ait-Ghezala G, Bachmeier C, Laco G, Beaulieu-Abdelahad D, Lin Y, Jin C, Crawford F, Mullan M. The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-\u03b2 production and Tau hyperphosphorylation. J Biol Chem. 2014;289(49):33927\u201344.","journal-title":"J Biol Chem"},{"issue":"1","key":"2886_CR109","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1515\/tnsci-2022-0218","volume":"13","author":"Z Mai","year":"2022","unstructured":"Mai Z, Wei W, Yu H, Chen Y, Wang Y, Ding Y. Molecular recognition of the interaction between ApoE and the TREM2 protein. Transl Neurosci. 2022;13(1):93\u2013103.","journal-title":"Transl Neurosci"},{"issue":"3","key":"2886_CR110","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/psyg.13091","volume":"24","author":"E Mori","year":"2024","unstructured":"Mori E, Ikeda M, Iseki E, Katayama S, Nagahama Y, Ohdake M, Takase T. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study. Psychogeriatrics. 2024;24(3):542\u201354.","journal-title":"Psychogeriatrics"},{"issue":"1","key":"2886_CR111","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group. Neurology. 1998;50(1):136\u201345.","journal-title":"Neurology"},{"issue":"10","key":"2886_CR112","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/cns.12158","volume":"19","author":"MR Farlow","year":"2013","unstructured":"Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 133 mg\/24 h versus 46 mg\/24 h in severe Alzheimer\u2019s dementia. CNS Neurosc Ther. 2013;19(10):745\u201352.","journal-title":"CNS Neurosc Ther"},{"issue":"7184","key":"2886_CR113","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M R\u00f6sler","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, St\u00e4helin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ. 1999;318(7184):633\u20138.","journal-title":"BMJ"},{"issue":"11","key":"2886_CR114","first-page":"1747","volume":"11","author":"AWY Lim","year":"2024","unstructured":"Lim AWY, Schneider L, Loy C. Galantamine for dementia due to Alzheimer\u2019s disease and mild cognitive impairment. Cochr Database Syst Rev. 2024;11(11):1747.","journal-title":"Cochr Database Syst Rev."},{"issue":"1","key":"2886_CR115","first-page":"Cd001747","volume":"2006","author":"C Loy","year":"2006","unstructured":"Loy C, Schneider L. Galantamine for Alzheimer\u2019s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;2006(1):Cd001747.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2886_CR116","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O\u2019Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2012;366(10):893\u2013903.","journal-title":"N Engl J Med"},{"issue":"S21","key":"2886_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/alz.077315","volume":"19","author":"O Schuh","year":"2023","unstructured":"Schuh O, Khanna D. Review of clinical trials showing the efficacy of memantine in patients with Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(S21): e077315.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2886_CR118","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis."},{"issue":"1","key":"2886_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"2886_CR120","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Bohorquez SS, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79(8):758\u201367.","journal-title":"JAMA Neurol"},{"issue":"14","key":"2886_CR121","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: lauriet. Neurology. 2023;101(14):e1391\u2013401.","journal-title":"Neurology"},{"issue":"12","key":"2886_CR122","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M, Kong J, O\u2019Gorman J, Ratti E, Rajagovindan R, Viollet L, Huang E, Sharma S, Racine AM, Czerkowicz J, Graham D, Li Y, Hering H, Haeberlein SB. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nat Aging. 2023;3(12):1591\u2013601.","journal-title":"Nat Aging"},{"issue":"8","key":"2886_CR123","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI, H\u00f6glinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O\u2019Gorman J, Haeberlein SB. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451\u20137.","journal-title":"Nat Med"},{"issue":"17","key":"2886_CR124","doi-asserted-by":"publisher","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","volume":"290","author":"CR Harrington","year":"2015","unstructured":"Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J Biol Chem. 2015;290(17):10862\u201375.","journal-title":"J Biol Chem"},{"issue":"16","key":"2886_CR125","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/ijms22168975","volume":"22","author":"L Mart\u00ednez-Gonz\u00e1lez","year":"2021","unstructured":"Mart\u00ednez-Gonz\u00e1lez L, Gonzalo-Consuegra C, G\u00f3mez-Almer\u00eda M, Porras G, de Lago E, Mart\u00edn-Requero \u00c1, Mart\u00ednez A. Tideglusib, a non-ATP competitive inhibitor of GSK-3\u03b2 as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22(16):8975.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2886_CR126","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M, Yeh F, Schwabe T, Paul R, Kenkare-Mitra S, Rosenthal A. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2024;16(1):235.","journal-title":"Alzheimer's Res Ther"},{"issue":"S9","key":"2886_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/alz.057872","volume":"17","author":"C Barnum","year":"2021","unstructured":"Barnum C, Tesi R, Malberg J. Phase 1b study of XPro1595 in Alzheimer\u2019s patients with biomarkers of inflammation. Alzheimers Dement. 2021;17(S9): e057872.","journal-title":"Alzheimers Dement"},{"key":"2886_CR128","doi-asserted-by":"publisher","first-page":"895017","DOI":"10.3389\/fncel.2023.895017","volume":"17","author":"KP MacPherson","year":"2023","unstructured":"MacPherson KP, Eidson LN, Houser MC, Weiss BE, Gollihue JL, Herrick MK, de Sousa Rodrigues ME, Sniffen L, Weekman EM, Hamilton AM, Kelly SD, Oliver DL, Yang Y, Chang J, Sampson TR, Norris CM, Tansey MG. Soluble TNF mediates amyloid-independent, diet-induced alterations to immune and neuronal functions in an Alzheimer\u2019s disease mouse model. Front Cell Neurosci. 2023;17:895017.","journal-title":"Front Cell Neurosci"},{"issue":"30","key":"2886_CR129","doi-asserted-by":"publisher","first-page":"e39027","DOI":"10.1097\/MD.0000000000039027","volume":"103","author":"J Haroon","year":"2024","unstructured":"Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya JR, Zielinski M, Venkatraman V, Goodenowe D, Hofmeister K, Zhang J, Ahlem C, Reading C, Palumbo J, Pourat B, Kuhn T, Jordan S. A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias. Medicine (Baltimore). 2024;103(30):e39027.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2886_CR130","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/nmt-2021-0022","volume":"11","author":"CL Reading","year":"2021","unstructured":"Reading CL, Ahlem CN, Murphy MF. NM101 Phase III study of NE3107 in Alzheimer\u2019s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener Dis Manag. 2021;11(4):289\u201398.","journal-title":"Neurodegener Dis Manag"},{"issue":"6","key":"2886_CR131","first-page":"399","volume":"10","author":"JS Tauskela","year":"2007","unstructured":"Tauskela JS. MitoQ\u2013a mitochondria-targeted antioxidant. IDrugs. 2007;10(6):399\u2013412.","journal-title":"IDrugs"},{"issue":"3","key":"2886_CR132","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmet.2022.02.001","volume":"34","author":"B Brakedal","year":"2022","unstructured":"Brakedal B, D\u00f6lle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlm\u00fcller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Gr\u00fcner R, Eidelberg D, Tzoulis C. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson\u2019s disease. Cell Metab. 2022;34(3):396-407.e6.","journal-title":"Cell Metab"},{"issue":"2","key":"2886_CR133","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ajcn\/nqy132","volume":"108","author":"OL Dollerup","year":"2018","unstructured":"Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, St\u00f8dkilde-J\u00f8rgensen H, M\u00f8ller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343\u201353.","journal-title":"Am J Clin Nutr"},{"key":"2886_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2024.101846","volume":"75","author":"X Du","year":"2024","unstructured":"Du X, Zeng Q, Luo Y, He L, Zhao Y, Li N, Han C, Zhang G, Liu W. Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction. Mitochondrion. 2024;75: 101846.","journal-title":"Mitochondrion"},{"issue":"6","key":"2886_CR135","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s43587-023-00416-y","volume":"3","author":"JB Mannick","year":"2023","unstructured":"Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging. 2023;3(6):642\u201360.","journal-title":"Nature Aging"},{"issue":"1","key":"2886_CR136","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41398-024-02755-9","volume":"14","author":"SY Cho","year":"2024","unstructured":"Cho SY, Kim EW, Park SJ, Phillips BU, Jeong J, Kim H, Heath CJ, Kim D, Jang Y, L\u00f3pez-Cruz L, Saksida LM, Bussey TJ, Lee DY, Kim E. Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer\u2019s model mice. Transl Psychiatry. 2024;14(1):34.","journal-title":"Transl Psychiatry"},{"key":"2886_CR137","doi-asserted-by":"publisher","first-page":"1440334","DOI":"10.3389\/fnins.2024.1440334","volume":"18","author":"CM Ou","year":"2024","unstructured":"Ou CM, Xue WW, Liu D, Ma L, Xie HT, Ning K. Stem cell therapy in Alzheimer\u2019s disease: current status and perspectives. Front Neurosci. 2024;18:1440334.","journal-title":"Front Neurosci"},{"issue":"1","key":"2886_CR138","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-016-0289-5","volume":"23","author":"LT Wang","year":"2016","unstructured":"Wang LT, Ting CH, Yen ML, Liu KJ, Sytwu HK, Wu KK, Yen BL. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. J Biomed Sci. 2016;23(1):76.","journal-title":"J Biomed Sci"},{"issue":"3","key":"2886_CR139","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1055\/s-0044-1788044","volume":"11","author":"Z Li","year":"2024","unstructured":"Li Z, Han Z, Han ZC. Mesenchymal stem cells in clinical trials for immune disorders. Glob Med Genet. 2024;11(3):196\u20139.","journal-title":"Glob Med Genet"},{"issue":"2","key":"2886_CR140","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-2010-1390","volume":"20","author":"NG Faux","year":"2010","unstructured":"Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. PBT2 rapidly improves cognition in Alzheimer\u2019s Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509\u201316.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"2886_CR141","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","volume":"7","author":"L Lannfelt","year":"2008","unstructured":"Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW. Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for Alzheimer\u2019s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. The Lancet Neurology. 2008;7(9):779\u201386.","journal-title":"The Lancet Neurology"},{"issue":"1","key":"2886_CR142","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaneurol.2024.3733","volume":"82","author":"S Ayton","year":"2025","unstructured":"Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C, Goh AMY, Kalinowski P, Kyndt C, Lai R, Lim YY, Maruff P, O\u2019Brien TJ, Rowe C, Salvado O, Schofield PW, Spino M, Tricta F, Wagen A, Williams R, Woodward M, Bush AI. Deferiprone in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2025;82(1):11\u20138.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2886_CR143","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jb\/mvae091","volume":"177","author":"M Suda","year":"2025","unstructured":"Suda M, Tchkonia T, Kirkland JL, Minamino T. Targeting senescent cells for the treatment of age-associated diseases. J Biochem. 2025;177(3):177\u201387.","journal-title":"J Biochem"},{"key":"2886_CR144","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson LJ, Prata LG, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446\u201356.","journal-title":"EBioMedicine"},{"issue":"S6","key":"2886_CR145","doi-asserted-by":"publisher","DOI":"10.1002\/alz.090729","volume":"20","author":"MN Sabbagh","year":"2024","unstructured":"Sabbagh MN, Chezem WR, Jin K, Missling CU, Anavex Life Sciences Research Group. Blarcamesine in early Alzheimer disease phase 2b\/3 randomized clinical trial. Alzheimers Dementia. 2024;20(S6): e090729.","journal-title":"Alzheimers Dementia."},{"issue":"1","key":"2886_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane S, Grimmer T, Teo K, O\u2019Brien TJ, Woodward M, Grunfeld J, Mander A, Brodtmann A, Brew BJ, Morris P, Short C, Kurrle S, Lai R, Bharadwaj S, Drysdale P, Sturm J, Lewis SJG, Barton D, Kalafatis C, Sharif S, Perry R, Mannering N, MacSweeney JE, Pearson S, Evans C, Krishna V, Thompson A, Munisamy M, Bhatt N, Asher A, Connell S, Lynch J, Rutgers SM, Dautzenberg PL, Prins N, Oschmann P, Fr\u00f6lich L, Tacik P, Peters O, Wiltfang J, Henri-Bhargava A, Smith E, Pasternak S, Frank A, Chertkow H, Ingram J, Hsiung GR, Brittain R, Tartaglia C, Cohen S, Villa LM, Gordon E, Jubault T, Guizard N, Tucker A, Kaufmann WE, Jin K, Chezem WR, Missling CU, Sabbagh MN. Blarcamesine for the treatment of early Alzheimer\u2019s disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial. J Prev Alzheimers Dis. 2025;12(1): 100016.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2886_CR147","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","volume":"35","author":"M Hallschmid","year":"2021","unstructured":"Hallschmid M. Intranasal insulin for Alzheimer\u2019s disease. CNS Drugs. 2021;35(1):21\u201337.","journal-title":"CNS Drugs"},{"issue":"12","key":"2886_CR148","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661\u201372.","journal-title":"Alzheimers Dement"},{"key":"2886_CR149","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251351329","author":"W Wang","year":"2025","unstructured":"Wang W, Davis PB, Qi X, Gurney M, Perry G, Volkow ND, Kaelber DC, Xu R. Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J Alzheimers Dis. 2025. https:\/\/doi.org\/10.1177\/13872877251351329.","journal-title":"J Alzheimers Dis"},{"key":"2886_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2024.102442","volume":"41","author":"B Chakraborty","year":"2024","unstructured":"Chakraborty B, Patel G, Padhan B, Das J, Patel M. Evolution of lipid nanoparticles as charioteers of Alzheimer\u2019s disease therapeutics. Appl Mater Today. 2024;41: 102442.","journal-title":"Appl Mater Today"},{"issue":"10","key":"2886_CR151","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41575-024-00977-2","volume":"21","author":"J Goldney","year":"2024","unstructured":"Goldney J, Davies MJ. GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction. Nat Rev Gastroenterol Hepatol. 2024;21(10):664\u20136.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"2886_CR152","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/YCO.0000000000000605","volume":"33","author":"C Angeloni","year":"2020","unstructured":"Angeloni C, Businaro R, Vauzour D. The role of diet in preventing and reducing cognitive decline. Curr Opin Psychiatry. 2020;33(4):432\u20138.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"2886_CR153","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/nu12041019","volume":"12","author":"F Vinciguerra","year":"2020","unstructured":"Vinciguerra F, Graziano M, Hagn\u00e4s M, Frittitta L, Tumminia A. Influence of the Mediterranean and ketogenic diets on cognitive status and decline: a narrative review. Nutrients. 2020;12(4):1019.","journal-title":"Nutrients"},{"issue":"17","key":"2886_CR154","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.3390\/nu15173680","volume":"15","author":"A Santangelo","year":"2023","unstructured":"Santangelo A, Corsello A, Spolidoro GCI, Trovato CM, Agostoni C, Orsini A, Milani GP, Peroni DG. The influence of ketogenic diet on gut microbiota: potential benefits, risks and indications. Nutrients. 2023;15(17):3680.","journal-title":"Nutrients"},{"issue":"10","key":"2886_CR155","volume":"14","author":"IM Dighriri","year":"2022","unstructured":"Dighriri IM, Alsubaie AM, Hakami FM, Hamithi DM, Alshekh MM, Khobrani FA, Dalak FE, Hakami AA, Alsueaadi EH, Alsaawi LS, Alshammari SF, Alqahtani AS, Alawi IA, Aljuaid AA, Tawhari MQ. Effects of omega-3 polyunsaturated fatty acids on brain functions: a systematic review. Cureus. 2022;14(10): e30091.","journal-title":"Cureus"},{"issue":"1","key":"2886_CR156","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/MOL.0000000000000862","volume":"34","author":"FK Welty","year":"2023","unstructured":"Welty FK. Omega-3 fatty acids and cognitive function. Curr Opin Lipidol. 2023;34(1):12\u201321.","journal-title":"Curr Opin Lipidol"},{"key":"2886_CR157","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.nbd.2015.11.004","volume":"85","author":"KM Moore","year":"2016","unstructured":"Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, Cirrito JR, Yuede CM, Zimmerman SD, Timson BF. A spectrum of exercise training reduces soluble A\u03b2 in a dose-dependent manner in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2016;85:218\u201324.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"2886_CR158","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/antiox13050573","volume":"13","author":"Q Meng","year":"2024","unstructured":"Meng Q, Su CH. The impact of physical exercise on oxidative and nitrosative stress: balancing the benefits and risks. Antioxidants (Basel). 2024;13(5):573.","journal-title":"Antioxidants. (Basel)"},{"issue":"3","key":"2886_CR159","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.arr.2006.04.002","volume":"5","author":"B Martin","year":"2006","unstructured":"Martin B, Mattson MP, Maudsley S. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev. 2006;5(3):332\u201353.","journal-title":"Ageing Res Rev"},{"key":"2886_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2020.111144","volume":"142","author":"SM Muscat","year":"2020","unstructured":"Muscat SM, Barrientos RM. Lifestyle modifications with anti-neuroinflammatory benefits in the aging population. Exp Gerontol. 2020;142: 111144.","journal-title":"Exp Gerontol"},{"key":"2886_CR161","doi-asserted-by":"publisher","first-page":"1147177","DOI":"10.3389\/fnins.2023.1147177","volume":"17","author":"I Xu Lou","year":"2023","unstructured":"Xu Lou I, Ali K, Chen Q. Effect of nutrition in Alzheimer\u2019s disease: a systematic review. Front Neurosci. 2023;17:1147177.","journal-title":"Front Neurosci"},{"issue":"1","key":"2886_CR162","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13195-021-00788-6","volume":"13","author":"A Nous","year":"2021","unstructured":"Nous A, Engelborghs S, Smolders I. Melatonin levels in the Alzheimer\u2019s disease continuum: a systematic review. Alzheimers Res Ther. 2021;13(1):52.","journal-title":"Alzheimers Res Ther"},{"key":"2886_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110887","volume":"132","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang J, Wan J, Liu A, Sun J. Melatonin regulates A\u03b2 production\/clearance balance and A\u03b2 neurotoxicity: a potential therapeutic molecule for Alzheimer\u2019s disease. Biomed Pharmacother. 2020;132: 110887.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"2886_CR164","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2174\/1570159X15666170313123454","volume":"15","author":"M Shukla","year":"2017","unstructured":"Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J. Mechanisms of melatonin in alleviating Alzheimer\u2019s disease. Curr Neuropharmacol. 2017;15(7):1010\u201331.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"2886_CR165","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41401-024-01398-2","volume":"46","author":"C-Z Zhu","year":"2025","unstructured":"Zhu C-Z, Li G-Z, Lyu H-F, Lu Y-Y, Li Y, Zhang X-N. Modulation of autophagy by melatonin and its receptors: implications in brain disorders. Acta Pharmacol Sin. 2025;46(3):525\u201338.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"2886_CR166","doi-asserted-by":"publisher","first-page":"17841","DOI":"10.1038\/s41598-023-45220-1","volume":"13","author":"C Nopparat","year":"2023","unstructured":"Nopparat C, Boontor A, Kutpruek S, Govitrapong P. The role of melatonin in amyloid beta-induced inflammation mediated by inflammasome signaling in neuronal cell lines. Sci Rep. 2023;13(1):17841.","journal-title":"Sci Rep"},{"issue":"3","key":"2886_CR167","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/157015910792246137","volume":"8","author":"H He","year":"2010","unstructured":"He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol. 2010;8(3):211\u20137.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"2886_CR168","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41398-021-01464-x","volume":"11","author":"LM Melhuish Beaupre","year":"2021","unstructured":"Melhuish Beaupre LM, Brown GM, Gon\u00e7alves VF, Kennedy JL. Melatonin\u2019s neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. Transl Psychiatry. 2021;11(1):339.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"2886_CR169","first-page":"211","volume":"3","author":"RA Hansen","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211\u201325.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"2886_CR170","doi-asserted-by":"publisher","first-page":"2270781","DOI":"10.1080\/14756366.2023.2270781","volume":"38","author":"D Zou","year":"2023","unstructured":"Zou D, Liu R, Lv Y, Guo J, Zhang C, Xie Y. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer\u2019s disease. J Enzyme Inhib Med Chem. 2023;38(1):2270781.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"2886_CR171","doi-asserted-by":"publisher","first-page":"12214","DOI":"10.1038\/s41598-022-16476-w","volume":"12","author":"M Zuin","year":"2022","unstructured":"Zuin M, Cherubini A, Volpato S, Ferrucci L, Zuliani G. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Sci Rep. 2022;12(1):12214.","journal-title":"Sci Rep"},{"issue":"7","key":"2886_CR172","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.str.2018.05.004","volume":"26","author":"A Yu","year":"2018","unstructured":"Yu A, Lau AY. Glutamate and glycine binding to the NMDA receptor. Structure. 2018;26(7):1035-1043.e2.","journal-title":"Structure"},{"issue":"6","key":"2886_CR173","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2013a review of preclinical data. Neuropharmacology. 1999;38(6):735\u201367.","journal-title":"Neuropharmacology"},{"issue":"7","key":"2886_CR174","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/15376516.2023.2202730","volume":"33","author":"J Kassa","year":"2023","unstructured":"Kassa J, Zdarova Karasova J. Combination of acetylcholinesterase inhibitors and NMDA receptor antagonists increases survival rate in soman-poisoned mice. Toxicol Mech Methods. 2023;33(7):590\u20135.","journal-title":"Toxicol Mech Methods"},{"issue":"1","key":"2886_CR175","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","volume":"28","author":"W Wu","year":"2023","unstructured":"Wu W, Ji Y, Wang Z, Wu X, Li J, Gu F, Chen Z, Wang Z. The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023;28(1):544.","journal-title":"Eur J Med Res"},{"issue":"7","key":"2886_CR176","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs. 2023;83(7):569\u201376.","journal-title":"Drugs"},{"issue":"7618","key":"2886_CR177","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"1","key":"2886_CR178","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.","journal-title":"Alzheimers Res Ther"},{"key":"2886_CR179","doi-asserted-by":"publisher","first-page":"394632023120983","DOI":"10.1177\/03946320231209839","volume":"37","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Chowdhury NS. Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer\u2019s disease: a systematic review. Int J Immunopathol Pharmacol. 2023;37:3946320231209839.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"7","key":"2886_CR180","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/acn3.52042","volume":"11","author":"RB Vukmir","year":"2024","unstructured":"Vukmir RB. Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy. Ann Clin Transl Neurol. 2024;11(7):1669\u201380.","journal-title":"Ann Clin Transl Neurol"},{"issue":"29","key":"2886_CR181","doi-asserted-by":"publisher","first-page":"eabo3610","DOI":"10.1126\/sciadv.abo3610","volume":"8","author":"N Singh","year":"2022","unstructured":"Singh N, Das B, Zhou J, Hu X, Yan R. Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. Sci Adv. 2022;8(29):eabo3610.","journal-title":"Sci Adv"},{"issue":"1","key":"2886_CR182","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/med.21622","volume":"40","author":"NM Moussa-Pacha","year":"2020","unstructured":"Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH. BACE1 inhibitors: Current status and future directions in treating Alzheimer\u2019s disease. Med Res Rev. 2020;40(1):339\u201384.","journal-title":"Med Res Rev"},{"key":"2886_CR183","first-page":"10","volume":"4","author":"RR Tampi","year":"2021","unstructured":"Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context. 2021;4:10.","journal-title":"Drugs Context."},{"issue":"9","key":"2886_CR184","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41582-021-00540-6","volume":"17","author":"J Karlawish","year":"2021","unstructured":"Karlawish J, Grill JD. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nat Rev Neurol. 2021;17(9):523\u20134.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"2886_CR185","doi-asserted-by":"publisher","first-page":"943","DOI":"10.17219\/acem\/171379","volume":"32","author":"M Kurkinen","year":"2023","unstructured":"Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer\u2019s disease. Adv Clin Exp Med. 2023;32(9):943\u20137.","journal-title":"Adv Clin Exp Med"},{"issue":"10367","key":"2886_CR186","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(22)02480-1","volume":"400","author":"L The","year":"2022","unstructured":"The L. Lecanemab for Alzheimer\u2019s disease: tempering hype and hope. Lancet. 2022;400(10367):1899.","journal-title":"Lancet"},{"issue":"2","key":"2886_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.japhar.2025.100015","volume":"2","author":"J Han","year":"2025","unstructured":"Han J, Fang Y, Campbell N. Real-world safety profile of lecanemab: a disproportionality analysis of adverse events in the FDA adverse event reporting system. JAPhA Pharmacotherapy. 2025;2(2): 100015.","journal-title":"JAPhA Pharmacotherapy"},{"issue":"1","key":"2886_CR188","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M, Yeh F, Schwabe T, Paul R, Kenkare-Mitra S, Rosenthal A. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):235.","journal-title":"Alzheimers Res Ther"},{"key":"2886_CR189","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","volume":"102","author":"KP MacPherson","year":"2017","unstructured":"MacPherson KP, Sompol P, Kannarkat GT, Chang J, Sniffen L, Wildner ME, Norris CM, Tansey MG. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol Dis. 2017;102:81\u201395.","journal-title":"Neurobiol Dis"},{"issue":"10","key":"2886_CR190","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.1007\/s12035-018-0973-4","volume":"55","author":"L Bonfili","year":"2018","unstructured":"Bonfili L, Cecarini V, Cuccioloni M, Angeletti M, Berardi S, Scarpona S, Rossi G, Eleuteri AM. SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model. Mol Neurobiol. 2018;55(10):7987\u20138000.","journal-title":"Mol Neurobiol"},{"key":"2886_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.arres.2022.100037","volume":"5","author":"LA Sulaimon","year":"2022","unstructured":"Sulaimon LA, Afolabi LO, Adisa RA, Ayankojo AG, Afolabi MO, Adewolu AM, Wan X. Pharmacological significance of MitoQ in ameliorating mitochondria-related diseases. Adv Redox Res. 2022;5: 100037.","journal-title":"Adv Redox Res"},{"issue":"1","key":"2886_CR192","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-023-00336-2","volume":"12","author":"B Yulug","year":"2023","unstructured":"Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Lam S, Velioglu HA, Yang H, Coskun E, Idil E, Nogaylar R, Ozsimsek A, Bayram C, Bolat I, Oner S, Tozlu OO, Arslan ME, Hacimuftuoglu A, Yildirim S, Arif M, Shoaie S, Zhang C, Nielsen J, Turkez H, Bor\u00e9n J, Uhl\u00e9n M, Mardinoglu A. Combined metabolic activators improve cognitive functions in Alzheimer\u2019s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener. 2023;12(1):4.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"2886_CR193","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.3390\/life13112156","volume":"13","author":"A Srivastava","year":"2023","unstructured":"Srivastava A, Johnson M, Renna HA, Sheehan KM, Ahmed S, Palaia T, Pinkhasov A, Gomolin IH, De Leon J, Reiss AB. Therapeutic potential of P110 peptide: new insights into treatment of Alzheimer\u2019s disease. Life. 2023;13(11):2156.","journal-title":"Life"},{"issue":"41","key":"2886_CR194","doi-asserted-by":"publisher","first-page":"29789","DOI":"10.1039\/D4RA05517A","volume":"14","author":"M Li","year":"2024","unstructured":"Li M, Kong D, Meng L, Wang Z, Bai Z, Wu G. Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH(2)) derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. RSC Adv. 2024;14(41):29789\u201399.","journal-title":"RSC Adv"},{"issue":"8","key":"2886_CR195","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1080\/15548627.2019.1615823","volume":"15","author":"JM Carosi","year":"2019","unstructured":"Carosi JM, Sargeant TJ. Rapamycin and Alzheimer disease: a double-edged sword? Autophagy. 2019;15(8):1460\u20132.","journal-title":"Autophagy"},{"key":"2886_CR196","doi-asserted-by":"publisher","first-page":"1433030","DOI":"10.3389\/fphar.2024.1433030","volume":"15","author":"H Lin","year":"2024","unstructured":"Lin H, Zhang C, Gao Y, Zhou Y, Ma B, Jiang J, Long X, Yimamu N, Zhong K, Li Y, Cui X, Wang H. HLH-30\/TFEB modulates autophagy to improve proteostasis in A\u03b2 transgenic Caenorhabditis elegans. Front Pharmacol. 2024;15:1433030.","journal-title":"Front Pharmacol"},{"key":"2886_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120299","volume":"291","author":"M Sanati","year":"2022","unstructured":"Sanati M, Aminyavari S, Afshari AR, Sahebkar A. Mechanistic insight into the role of metformin in Alzheimer\u2019s disease. Life Sci. 2022;291: 120299.","journal-title":"Life Sci"},{"key":"2886_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111286","volume":"137","author":"G Lu","year":"2021","unstructured":"Lu G, Wu Z, Shang J, Xie Z, Chen C, Zhang C. The effects of metformin on autophagy. Biomed Pharmacother. 2021;137: 111286.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2886_CR199","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/antiox12020533","volume":"12","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2023","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Ag\u00fandez JAG. Coenzyme Q10 and dementia: a systematic review. Antioxidants (Basel). 2023;12(2):533.","journal-title":"Antioxidants (Basel)"},{"issue":"s1","key":"2886_CR200","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/JAD-220721","volume":"94","author":"X Chen","year":"2023","unstructured":"Chen X, Jiang S, Wang R, Bao X, Li Y. Neural stem cells in the treatment of Alzheimer\u2019s disease: current status, challenges, and future prospects. J Alzheimers Dis. 2023;94(s1):S173-s186.","journal-title":"J Alzheimers Dis"},{"key":"2886_CR201","doi-asserted-by":"publisher","first-page":"7834421","DOI":"10.1155\/2021\/7834421","volume":"2021","author":"AE Hern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez AE, Garc\u00eda E. Mesenchymal stem cell therapy for Alzheimer\u2019s disease. Stem Cells Int. 2021;2021:7834421.","journal-title":"Stem Cells Int"},{"key":"2886_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155614","volume":"263","author":"WH Almalki","year":"2024","unstructured":"Almalki WH, Almujri SS. Therapeutic approaches to microglial dysfunction in Alzheimer\u2019s disease: enhancing phagocytosis and metabolic regulation. Pathol Res Pract. 2024;263: 155614.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"2886_CR203","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.cmet.2017.06.005","volume":"26","author":"V Nikoletopoulou","year":"2017","unstructured":"Nikoletopoulou V, Sidiropoulou K, Kallergi E, Dalezios Y, Tavernarakis N. Modulation of autophagy by BDNF underlies synaptic plasticity. Cell Metab. 2017;26(1):230-242.e5.","journal-title":"Cell Metab"},{"key":"2886_CR204","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2016.04.013","volume":"327\u2013328","author":"MA Santos","year":"2016","unstructured":"Santos MA, Chand K, Chaves S. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer\u2019s disease. Coord Chem Rev. 2016;327\u2013328:287\u2013303.","journal-title":"Coord Chem Rev"},{"key":"2886_CR205","doi-asserted-by":"crossref","unstructured":"M.M. Gonzales, V.R. Garbarino, E. Marques Zilli, R.C. Petersen, J.L. Kirkland, T. Tchkonia, N. Musi, S. Seshadri, S. Craft, M.E. Orr, Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial, J Prev Alzheimers Dis 9(1) (2022) 22\u201329.","DOI":"10.14283\/jpad.2021.62"},{"issue":"7","key":"2886_CR206","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13658","volume":"21","author":"W-I Ryu","year":"2022","unstructured":"Ryu W-I, Shen M, Lee Y, Healy RA, Bormann MK, Cohen BM, Sonntag K-C. Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer\u2019s disease. Aging Cell. 2022;21(7): e13658.","journal-title":"Aging Cell"},{"issue":"6","key":"2886_CR207","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s43587-023-00416-y","volume":"3","author":"JB Mannick","year":"2023","unstructured":"Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat Aging. 2023;3(6):642\u201360.","journal-title":"Nat Aging"},{"issue":"2","key":"2886_CR208","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.intimp.2014.01.028","volume":"19","author":"M Kajiya","year":"2014","unstructured":"Kajiya M, Takeshita K, Kittaka M, Matsuda S, Ouhara K, Takeda K, Takata T, Kitagawa M, Fujita T, Shiba H, Kurihara H. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB\u2013ERK\/Akt signaling cascade. Int Immunopharmacol. 2014;19(2):245\u201352.","journal-title":"Int Immunopharmacol"},{"key":"2886_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113286","volume":"329","author":"GP Eckert","year":"2020","unstructured":"Eckert GP, Eckert SH, Eckmann J, Hagl S, Muller WE, Friedland K. Olesoxime improves cerebral mitochondrial dysfunction and enhances A\u03b2 levels in preclinical models of Alzheimer\u2019s disease. Exp Neurol. 2020;329: 113286.","journal-title":"Exp Neurol"},{"issue":"3","key":"2886_CR210","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JAD-150307","volume":"47","author":"TS Salameh","year":"2015","unstructured":"Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, Morley JE, Farr SA, Banks WA. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis. 2015;47(3):715\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"10403","key":"2886_CR211","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705\u201319.","journal-title":"Lancet"},{"key":"2886_CR212","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M, Li JL, Ye YC, Cai HY, H\u00f6lscher C, Wu MN. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology. 2023;240: 109716.","journal-title":"Neuropharmacology"},{"issue":"1","key":"2886_CR213","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13543784.2017.1265504","volume":"26","author":"D Galimberti","year":"2017","unstructured":"Galimberti D, Scarpini E. Pioglitazone for the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2017;26(1):97\u2013101.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2886_CR214","doi-asserted-by":"publisher","first-page":"43701","DOI":"10.1038\/srep43701","volume":"7","author":"LA Johnson","year":"2017","unstructured":"Johnson LA, Torres ERS, Impey S, Stevens JF, Raber J. Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome. Sci Rep. 2017;7(1):43701.","journal-title":"Sci Rep"},{"key":"2886_CR215","unstructured":"L. Herbster, G. Pander, M.B. B\u00f6hmann, T. Eisenzapf, S. Wohlfart, E. M\u00fchlberg, W. Mier, G. Fricker, P. Uhl, Liposomes Containing Tetraether Lipids and Cell-Penetrating Peptides as Platform Technology for Oral Delivery of Peptides: A Comparative Study on GLP-1 Analogs, Nano Select n\/a(n\/a)  e70010."},{"issue":"2","key":"2886_CR216","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jnc.15112","volume":"156","author":"T Soares Martins","year":"2021","unstructured":"Soares Martins T, Trindade D, Vaz M, Campelo I, Almeida M, Trigo G, da Cruz e Silva OA, Henriques AG. Diagnostic and therapeutic potential of exosomes in Alzheimer\u2019s disease. J Neurochem. 2021;156(2):162\u201381.","journal-title":"J Neurochem"},{"key":"2886_CR217","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","volume":"130","author":"J Gupta","year":"2019","unstructured":"Gupta J, Fatima MT, Islam Z, Khan RH, Uversky VN, Salahuddin P. Nanoparticle formulations in the diagnosis and therapy of Alzheimer\u2019s disease. Int J Biol Macromol. 2019;130:515\u201326.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"2886_CR218","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acsbiomaterials.5c00465","volume":"11","author":"AK Mahanta","year":"2025","unstructured":"Mahanta AK, Chaulagain B, Gothwal A, Singh J. Engineered PLGA nanoparticles for brain-targeted codelivery of cannabidiol and pApoE2 through the intranasal route for the treatment of Alzheimer\u2019s disease. ACS Biomater Sci Eng. 2025;11(6):3533\u201346.","journal-title":"ACS Biomater Sci Eng"},{"key":"2886_CR219","doi-asserted-by":"publisher","first-page":"1510798","DOI":"10.3389\/fphar.2025.1510798","volume":"16","author":"J Jia","year":"2025","unstructured":"Jia J, Zhao S, Zhao J, Gao Y. Engineered nanoparticles for the treatment of Alzheimer\u2019s disease. Front Pharmacol. 2025;16:1510798.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2886_CR220","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biom6010006","volume":"6","author":"G \u0160imi\u0107","year":"2016","unstructured":"\u0160imi\u0107 G, Babi\u0107 Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milo\u0161evi\u0107 N, Ba\u017eadona D, Bu\u00e9e L, de Silva R, Di Giovanni G, Wischik C, Hof PR. Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules. 2016;6(1):6.","journal-title":"Biomolecules"},{"key":"2886_CR221","doi-asserted-by":"publisher","first-page":"1465871","DOI":"10.3389\/fnagi.2024.1465871","volume":"16","author":"W Cai","year":"2025","unstructured":"Cai W, Zhang H, Wu Y, Yao Y, Zhang J. Comparative the efficacy and safety of gosuranemab, semorinemab, tilavonemab, and zagotenemab in patients with Alzheimer\u2019s disease: a systematic review and network meta-analysis of randomized controlled trials. Front Aging Neurosci. 2025;16:1465871.","journal-title":"Front Aging Neurosci"},{"issue":"593","key":"2886_CR222","doi-asserted-by":"publisher","first-page":"eabb2639","DOI":"10.1126\/scitranslmed.abb2639","volume":"13","author":"G Ayalon","year":"2021","unstructured":"Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer\u2019s disease. Sci Transl Med. 2021;13(593):eabb2639.","journal-title":"Sci Transl Med"},{"issue":"3","key":"2886_CR223","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s13139-025-00908-2","volume":"59","author":"SM Tripathi","year":"2025","unstructured":"Tripathi SM, McNeil CJ, Staff RT, Murray AD, Wischik CM, Schelter B, Waiter GD. FDG-PET image classification in Alzheimer\u2019s Disease: from traditional visual analysis to advanced transfer learning. Nucl Med Mol Imaging. 2025;59(3):201\u20138.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"2886_CR224","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, H\u00fcll M, Rinne JO, Huppertz HJ, Calero M, Andr\u00e9s MV, G\u00f3mez-Carrillo B, Le\u00f3n T, del Ser T. A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis. 2015;45(1):75\u201388.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2886_CR225","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"AFT Arnsten","year":"2021","unstructured":"Arnsten AFT, Datta D, Del Tredici K, Braak H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease. Alzheimers Dement. 2021;17(1):115\u201324.","journal-title":"Alzheimers Dement"},{"key":"2886_CR226","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3389\/fnins.2019.01274","volume":"13","author":"S Takeda","year":"2019","unstructured":"Takeda S. Tau propagation as a diagnostic and therapeutic target for dementia: potentials and unanswered questions. Front Neurosci. 2019;13:1274.","journal-title":"Front Neurosci"},{"issue":"1","key":"2886_CR227","doi-asserted-by":"publisher","first-page":"14342","DOI":"10.1038\/s41598-023-41382-0","volume":"13","author":"H Geerts","year":"2023","unstructured":"Geerts H, Bergeler S, Walker M, van der Graaf PH, Courade JP. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model. Sci Rep. 2023;13(1):14342.","journal-title":"Sci Rep"},{"issue":"29","key":"2886_CR228","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2347-23.2024","volume":"44","author":"A Etxeberria","year":"2024","unstructured":"Etxeberria A, Shen YA, Vito S, Silverman SM, Imperio J, Lalehzadeh G, Soung AL, Du C, Xie L, Choy MK, Hsiao YC. Neutral or detrimental effects of TREM2 agonist antibodies in preclinical models of alzheimer\u2019s disease and multiple sclerosis. J Neurosci. 2024;44(29): e2347232024.","journal-title":"J Neurosci"},{"issue":"2","key":"2886_CR229","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuron.2022.12.032","volume":"111","author":"MT Heneka","year":"2023","unstructured":"Heneka MT. ApoE4 makes microglia trem(2)bling. Neuron. 2023;111(2):142\u20134.","journal-title":"Neuron"},{"issue":"8","key":"2886_CR230","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21(8):726\u201334.","journal-title":"Lancet Neurol"},{"issue":"9","key":"2886_CR231","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/neuonc\/noae087","volume":"26","author":"K Piper","year":"2024","unstructured":"Piper K, Kumar JI, Domino J, Tuchek C, Vogelbaum MA. Consensus review on strategies to improve delivery across the blood-brain barrier including focused ultrasound. Neuro Oncol. 2024;26(9):1545\u201356.","journal-title":"Neuro Oncol"},{"key":"2886_CR232","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.lanepe.2023.100657","volume":"29","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Wimo A, Handels R, Johansson G, Boada M, Engelborghs S, Fr\u00f6lich L, Jessen F, Kehoe PG, Kramberger M, de Mendon\u03c2a A. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023;29:100657.","journal-title":"Lancet Reg Health Eur."},{"key":"2886_CR233","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2025.2507427","author":"V Sanogo","year":"2025","unstructured":"Sanogo V, Saud Almutairi RD, Diaby V. Budget impact of lecanemab for medicare beneficiaries with early Alzheimer\u2019s disease in the United States: a subgroup analysis. Expert Rev Pharmacoecon Outcomes Res. 2025. https:\/\/doi.org\/10.1080\/14737167.2025.2507427.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02886-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:11:24Z","timestamp":1757236284000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02886-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":233,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02886-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"625"}}